[{"NetIncomeLossConverted_1_Q2_USD":897300000.0,"NetIncomeLossConverted_2_Q2_USD":1521900000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":109600000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":109700000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":1641400000.0,"EarningsPerShareDiluted_1_Q2_USD":7.61,"EarningsPerShareDiluted_2_Q2_USD":13.03,"StockholdersEquity_0_Q2_USD":9057400000.0,"RevenuesConverted_1_Q2_USD":1952000000.0,"RevenuesConverted_2_Q2_USD":3780200000.0,"Assets_0_Q2_USD":14428700000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":117900000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":116800000.0,"EarningsPerShareBasic_1_Q2_USD":8.19,"EarningsPerShareBasic_2_Q2_USD":13.87,"Ticker":"REGN","CIK":"872589","name":"REGENERON PHARMACEUTICALS, INC.","OfficialName":"Regeneron Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"77738004554.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"SP500","filed":"20200805"}]